click full compani updat
latest quarterli report
beat sale ep howev full year top bottom line guidanc lower
anticip neg impact especi
ep ahead estim consensu
ep guidanc lower includ fx impact
share vs prior last publish ep estim review
sale estim
consensu overal impact immateri product beat
estim includ gardasil larg due stock simponi isentress zetia
vytorin combin forecast product forecast
includ januvia singulair zepati keytruda cubicin remicad
nasonex combin forecast anim health sale
estim includ stock
sale guidanc lower prior includ fx
impact vs prior less guidanc assum neg impact due
pharma anim health estim two-
third pharma revenu physician-administ product
neg impact fewer doctor visit elect procedur keytruda implanon
bridion vaccin note like impact biggest hit expect
improv return full normal anim health hurt decreas protein
consumpt school/restaur closur fewer vet visit last publish
revenu estim review
gpm estim
estim sg estim net non-
oper expens forecast tax rate
estim share count forecast line
item guidanc gpm vs prior oper expens declin low singl
digit vs prior low singl digit rate increas net expens unchang
tax rate vs prior temporari paus share repurchas
product suppli remain intact advanc discuss three differ
viral vaccin platform therapeut assess antivir candid
collabor system biolog nih clinic trial
enrol patient on-going studi start new trial
keytruda ph data tnbc bladder rcc w/lenvima approv cscc tmb-
 tumor lynparza w/azn approv mcrpc ovarian mainten
pneumococc vaccin file adult investor call june spin-off
organon track complet list event follow page
pleas see page report import disclosur
cowen compani
cowen compani compani data
cowen compani
cowen compani
cowen compani
m-m-r ii cowen
cowen compani
time frameev ph data tnbc posit feb data nasopharyng carcinomaph data bladderkeytruda lenvimaphas data rccgefapix ii data endometriosi painful phase data chronic cough high dose met primari endpt ph data habp/vabp eecmid apr posit top-lin oct verti cv cv outcom data primari complet dec pneumococc vaccin phase dataregulatorykeytrudau approv dose option re-fil apr post feb crlu approv tmb-h tumor pdufa approv cscc pdufa file neo adjuv tnbc selumetinib w/azn eu approv pediatr neurofibromatosi type w/azn cn approv brcam breast canceru approval/eu file ovarian manten cancer pdufa approval/eu file brca/atm mcrpc profound pdufa file brcam ovarian cancerlynparza cediranib w/azn regulatori file ovarian cancerrecarbrioeu approv certain gram neg infect posit chmp dec approv habp/vabp pdufa file pneumococc vaccin regulatori file calljun et cowen
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio market cap/fre cash flow metric
failur pipelin product intellectu properti challeng econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
risk includ continu success exist portfolio notabl januvia vytorin
zetia isentress success pipelin product especi suvorex odanacatib
anacetrapib lambrolizumab success deal patent litig patent
expir pressur binari risk includ safeti issu involv odanacatib
improve-it studi vytorin
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
cowen compani llc affili make market stock merck secur
author report member author household long posit equiti secur merck
cowen compani llc compens research analyst activ servic intend benefit firm investor client individu compens determin research
analyst includ author report base varieti factor includ overal profit firm total revenu deriv sourc includ
revenu invest bank sale trade princip trade revenu cowen compani llc compens research analyst base specif invest
bank transact specif sale trade princip trade revenu
research report simultan avail client client websit research report client research report dissemin e-mail
made avail third-parti aggreg cowen compani llc respons redistribut research third parti aggreg select research report
avail print form addit electron form publish research report obtain firm client websit http //cowenlibrari bluematrix com/client/
inform opinion estim forecast date report subject chang without prior notif seek updat research appropri
variou regul may prevent us research report publish irregular interv appropri analyst judgement
inform subject secur may obtain offic research report publish sole inform purpos constru offer
sell solicit offer buy secur state offer solicit would illeg disclosur relat cowen compani llc
